GT Biopharma, Inc.

We are a clinical stage biopharmaceutical company focused on developing and commercializing new immuno-oncology products. Our products are based on our proprietary Tri-specific Killer Engager ("TriKE®") and Tetra-specific Killer Engager ("Dual Targeting TriKE®") fusion protein immune cell engager technology platforms. These platforms create proprietary therapeutics designed to harness and enhance the cancer-killing abilities of a patient's own natural killer cells ("NK cells"). Once bound to an NK cell, our molecules are designed to activate the NK cell to direct it to one or more specific proteins found on a particular type of cancer cell or virus-infected cell, leading to the death of the targeted cell. TriKE®s can be designed to target various tumor antigens, including B7-H3, HER2, CD33, and PDL1, on blood cancers or solid tumors and do not require patient-specific customization. We intend to use our TriKE® platform to bring immuno-oncology products to market that can treat a range of blood cancers, solid tumors, and potentially autoimmune disorders. The platform is scalable, and we are implementing processes to produce investigational new drug ("IND") ready molecules promptly after a specific TriKE® conceptual design. Specific drug candidates can then be advanced into clinical trials independently or through potential collaborations with partnering companies. Our initial work was conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr. Jeffrey Miller, Professor of Medicine, and the Interim Director at the Masonic Cancer Center.